Deciphering Prenatal Risks: Why Maternal Health, Not Medication, Often Drives Neurodevelopmental Outcomes
Posted innews OB/GYN & Women’s Health Psychiatry

Deciphering Prenatal Risks: Why Maternal Health, Not Medication, Often Drives Neurodevelopmental Outcomes

Recent large-scale cohort studies suggest that previously observed links between prenatal exposure to acid-suppressants or antipsychotics and neurodevelopmental disorders are largely due to familial confounding. Conversely, active maternal eating disorders remain a significant risk factor, highlighting the critical role of maternal health optimization.
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Posted inDiabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.
Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders
Posted inGeneral Surgery news Oncology

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-years in patients achieving a clinical complete response after neoadjuvant chemoradiation.
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Posted inInternal Medicine news Respiratory

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managing this debilitating and often refractory symptom.
Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD
Posted inDermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.